[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649706":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":152,"collaborators":10,"id":154,"slug":155,"hasResults":156,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":10,"eligibilityCriteria":160,"healthyVolunteers":156,"sex":161,"minAge":162,"maxAge":10,"enrollmentInfo":163,"targetDuration":10,"studyType":166,"phases":10,"briefSummary":167,"conditions":168,"keywords":10,"overallStatus":170,"whyStopped":10,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},{"fullName":5,"class":6},"Abbott Diabetes Care","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Type I Diabetic patients using a Continuous Dual Glucose Ketone Sensor (DGK) Monitoring System",null,"This is a multicentre, single arm, prospective, observational clinical study to determine DKA episodes in adult and pediatric people living with type 1 diabetes who will manage their diabetes by use of a Continuous Dual Glucose Ketone (DGK) sensor for 3 months",[13],"Device: Abbott Continuous Dual Glucose Ketone Monitoring System",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Abbott Continuous Dual Glucose Ketone Monitoring System","Participant will utilize the Abbott Continuous Dual Glucose Ketone Monitoring System in place of the Standard of Care",[9],[21],{"name":22,"affiliation":23,"role":24},"Shridhara Alva, PhD","Abbott Diabetes Care Inc","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Mohamed Nada Director, Clinical Affairs, PhD","CONTACT","510-749-5416","mohamed.nada@abbott.com",[32,53,75,92,108,122,135],{"facility":33,"status":10,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Optimal Clinical Trials (North)","Rosedale","Auckland","0632","New Zealand","NZ",{"type":40,"coordinates":41},"Point",[42,43],174.70714,-36.75143,{"lat":43,"lon":42},[46,50],{"name":47,"role":28,"phone":48,"phoneExt":10,"email":49},"Claudette Lionnet, MD","+64 9 303 4987","Claudette@optimalclinicaltrials.com",{"name":51,"role":28,"phone":48,"phoneExt":10,"email":52},"Kshemina Mhaskar","kshemina@optimalclinicaltrials.com",{"facility":54,"status":10,"city":55,"state":56,"zip":57,"country":37,"countryCode":38,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"New Zealand Clinical Research","Christchurch","Christchurch Central City","8011",{"type":40,"coordinates":59},[60,61],172.63333,-43.53333,{"lat":61,"lon":60},[64,68,72],{"name":65,"role":28,"phone":66,"phoneExt":10,"email":67},"Martin deBock, MD","+64 (0) 211956579","martin.debock@otago.ac.nz",{"name":69,"role":28,"phone":70,"phoneExt":10,"email":71},"Jo Sanders","+6433729477","jo.sanders@nzcr.co.nz",{"name":73,"role":74,"phone":10,"phoneExt":10,"email":10},"Marin debock, MD","PRINCIPAL_INVESTIGATOR",{"facility":76,"status":10,"city":77,"state":78,"zip":79,"country":37,"countryCode":38,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Health New Zealand-Southern","Dunedin","Otago","9016",{"type":40,"coordinates":81},[82,83],170.50361,-45.87416,{"lat":83,"lon":82},[86,90],{"name":87,"role":28,"phone":88,"phoneExt":10,"email":89},"Benjamin Wheeler, MD","0064223279429","ben.wheeler@otago.ac.nz",{"name":91,"role":74,"phone":10,"phoneExt":10,"email":10},"Ben Wheeler, MD",{"facility":93,"status":10,"city":35,"state":10,"zip":94,"country":37,"countryCode":38,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Optimal Clinical Trials","1010",{"type":40,"coordinates":96},[97,98],174.76349,-36.84853,{"lat":98,"lon":97},[101,104,107],{"name":102,"role":28,"phone":48,"phoneExt":10,"email":103},"Nah Y Baik, MD","Tina@optimalclinicaltrials.com",{"name":105,"role":28,"phone":48,"phoneExt":10,"email":106},"Kim AU","Kim.a@optimalclinicaltrials.com",{"name":102,"role":74,"phone":10,"phoneExt":10,"email":10},{"facility":109,"status":10,"city":110,"state":10,"zip":111,"country":37,"countryCode":38,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Aotearoa Diabetes Collective","Hamilton","3204",{"type":40,"coordinates":113},[114,115],175.28333,-37.78333,{"lat":115,"lon":114},[118],{"name":119,"role":28,"phone":120,"phoneExt":10,"email":121},"Ryan Y Paul, MD","07 834 0189","ryan.paul@tewhatuora.govt.nz",{"facility":123,"status":10,"city":124,"state":10,"zip":125,"country":37,"countryCode":38,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"Te Pae Hauora o Ruahine o Tararua \u002FMidCentral Health New Zealand","Palmerston North","4414",{"type":40,"coordinates":127},[128,129],175.61113,-40.35636,{"lat":129,"lon":128},[132],{"name":133,"role":28,"phone":10,"phoneExt":10,"email":134},"Helen Snell, MD","helen.snell@midcentraldhb.govt.nz",{"facility":54,"status":10,"city":136,"state":10,"zip":137,"country":37,"countryCode":38,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Wellington","6011",{"type":40,"coordinates":139},[140,141],174.77557,-41.28664,{"lat":141,"lon":140},[144,148],{"name":145,"role":28,"phone":146,"phoneExt":10,"email":147},"Dr. Jian Hui Feng, MD","6421338986","David.Feng@nzcr.co.nz",{"name":149,"role":28,"phone":150,"phoneExt":10,"email":151},"Trish Smith","+64 4 333 1726","Trish.Smith@nzcr.co.nz",{"type":153,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100649706","evaluating-the-occurrence-of-dka-in-people-with-type-i-diabetes-100649706",false,"NCT07739342","Evaluating the Occurrence of DKA in People With Type I Diabetes","Evaluating the Occurrence of DKA in People With Type 1 Diabetes","Inclusion Criteria:\n\n1. Aged at least 2 years old at the time of study enrollment.\n2. Diagnosis of type 1 diabetes with at least 12 months of diabetes medical history.\n3. In the investigator's opinion, the participant is willing to wear the sensor, follow study specific instructions, and perform all study tasks.\n4. Willing and able to provide written signed and dated informed consent (adults) or participant's parent\u002Flegal guardian must be willing and able to provide written signed and dated informed consent along with assent form completed by the participant for those mature enough to make their own decisions per investigator assessment (those less than 16 years of age).\n\nExclusion Criteria:\n\n1. In the investigator's opinion, the participant has a known (or suspected) allergy to medical grade adhesives at enrollment that would interfere with participant completing study required activities.\n2. In the investigator's opinion, the participant has concomitant medical condition(s) which could interfere with the study or present a risk to the safety or welfare of the participant or study staff.\n3. Participant is currently in another clinical study which may affect glucose or ketone management (or does so during the study).\n4. Participant is unsuitable for participation due to any other cause as determined by the investigator.\n5. Participant has implanted medical devices such as pacemakers or requires dialysis or is critically ill.","ALL","2 Years",{"count":164,"type":165},1200,"ESTIMATED","OBSERVATIONAL","This study will evaluate the occurrences of Diabetes-related Ketoacidosis (DKA) in adult and pediatric individuals living with Type I diabetes while managing diabetes with Abbott's Continuous Monitoring Systems.",[169],"Type 1 Diabetes","NOT_YET_RECRUITING","2026-07-28",{"date":173,"type":174},"2026-07-31","ACTUAL",{"date":176,"type":165},"2026-09",{"date":178,"type":165},"2027-12",{"name":5,"class":6},7]